Nuformix (LON:NFX) Reaches New 12-Month Low – What’s Next?

Nuformix plc (LON:NFX)’s stock price hit a new 52-week low on Tuesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00), with a volume of 3374588 shares changing hands. The stock had previously closed at GBX 0.06 ($0.00).

Nuformix Price Performance

The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The stock has a market capitalization of £491,586.00, a price-to-earnings ratio of -1.63 and a beta of 1.22. The business’s 50 day simple moving average is GBX 0.11 and its 200-day simple moving average is GBX 0.16.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.